PharmaCyte Biotech (NASDAQ:PMCB) is a biotech firm focusing on developing cellular therapies for cancer and diabetes using its unique live-cell encapsulation technology, Cell-in-a-Box®. This technology is designed to encase living cells that can convert inactive chemotherapy drugs into their active or cancer-killing form directly at the site of the cancer. PharmaCyte's primary project revolves around utilizing its technology for the treatment of inoperable pancreatic cancer, aiming to improve patient outcomes and quality of life. The company is also exploring the potential of Cell-in-a-Box® in the development of treatments for diabetes, with the goal of creating a bio-artificial pancreas for insulin-dependent diabetics. PharmaCyte's objectives include advancing its clinical trials and research, forming strategic partnerships, and achieving regulatory milestones to become a leader in cell-based therapies.